Here are five points:
1. In 2015, Titan Spine had $33.5 million in global sales.
2. The company’s fourth quarter sales equated to annualized run rate of $43.1 million.
3. Titan Spine sold about 10,000 Endoskeleton implants in 2015.
4. The company has more than 400 hospital customers globally and more than 110 distributors.
5. Titan Spine plans to release its nanoLOCK surface technology, which is the only FDA-cleared nanotechnology for spine.
“The considerable progress Titan Spine achieved in 2015 is a reflection of the interbody device market’s accelerating shift toward titanium implants, which is due, at least in part, to our continually expanding science and research,” said Peter Ullrich, chief executive officer, Titan Spine.
More articles on devices:
Mesoblast cell therapy shows positive results for patients with rheumatoid arthritis — 5 points
Smith & Nephew target of a large growth in short interest — 4 observations
43 spine, orthopedic devices receive FDA 510(k) clearance in January
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
